Genentech, UPenn End Herceptin Patent Row On Eve Of Trial

Law360, New York (June 8, 2012, 5:16 PM EDT) -- Genentech Inc. dropped its declaratory suit against the University of Pennsylvania on Friday, saying the parties had settled their patent infringement dispute related to the drug company’s breast cancer treatment Herceptin right before trial was due to start.

U.S. District Judge Lucy H. Koh signed off on Genentech’s motion to dismiss the case without prejudice after the parties notified the California federal court they had reached an “amicable settlement” just before trial was scheduled to begin Monday.

Roche Holding Ltd. subsidiary Genentech launched a declaratory suit...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.